Exelixis, Inc. (NASDAQ:EXEL) – Analysts at William Blair upped their Q2 2017 earnings per share (EPS) estimates for Exelixis in a research note issued to investors on Monday. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings of $0.03 per share for the quarter, up from their previous forecast of $0.01. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Exelixis’ Q3 2017 earnings at $0.03 EPS, FY2018 earnings at $0.43 EPS and FY2019 earnings at $1.09 EPS.

Several other equities analysts have also recently commented on the stock. CIBC started coverage on shares of Exelixis in a research note on Thursday, March 16th. They set a “market perform” rating on the stock. Oppenheimer Holdings, Inc. started coverage on shares of Exelixis in a research report on Thursday, March 16th. They set a “market perform” rating for the company. Cann started coverage on shares of Exelixis in a research report on Wednesday, March 15th. They set a “positive” rating for the company. Zacks Investment Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Finally, Needham & Company LLC started coverage on shares of Exelixis in a research report on Friday, March 31st. They set a “buy” rating and a $28.00 price objective for the company. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Exelixis currently has an average rating of “Buy” and a consensus target price of $19.22.

COPYRIGHT VIOLATION NOTICE: “Q2 2017 Earnings Forecast for Exelixis, Inc. Issued By William Blair (EXEL)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/12/q2-2017-earnings-forecast-for-exelixis-inc-issued-by-william-blair-exel.html.

Shares of Exelixis (NASDAQ:EXEL) opened at 25.41 on Wednesday. The company’s 50-day moving average is $20.79 and its 200-day moving average is $20.23. Exelixis has a 12-month low of $7.95 and a 12-month high of $25.68. The stock has a market cap of $7.43 billion, a P/E ratio of 1210.00 and a beta of 1.88.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. Exelixis had a net margin of 1.37% and a return on equity of 126.82%. The business’s revenue was up 425.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.27) earnings per share.

Several institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its position in Exelixis by 1.3% in the first quarter. Legal & General Group Plc now owns 84,763 shares of the biotechnology company’s stock worth $1,834,000 after buying an additional 1,078 shares in the last quarter. GSA Capital Partners LLP raised its position in Exelixis by 3.4% in the fourth quarter. GSA Capital Partners LLP now owns 38,589 shares of the biotechnology company’s stock worth $575,000 after buying an additional 1,271 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Exelixis by 14.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock worth $320,000 after buying an additional 1,838 shares in the last quarter. Teacher Retirement System of Texas raised its position in Exelixis by 17.8% in the first quarter. Teacher Retirement System of Texas now owns 21,734 shares of the biotechnology company’s stock worth $471,000 after buying an additional 3,287 shares in the last quarter. Finally, Martingale Asset Management L P raised its position in Exelixis by 5.9% in the first quarter. Martingale Asset Management L P now owns 59,428 shares of the biotechnology company’s stock worth $1,288,000 after buying an additional 3,301 shares in the last quarter. 80.69% of the stock is currently owned by institutional investors.

In related news, insider Patrick J. Haley sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Gisela Schwab sold 89,910 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $23.01, for a total transaction of $2,068,829.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 709,647 shares of company stock valued at $15,673,068. 5.10% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.